Amprologix Presents at ESCMID Global 2025
16 April 2025Mat Upton, CSO, presented the latest results from ongoing research at ESCMID Global 2025. ESCMID Global 2025 - the Congress of…
Mat Upton, CSO, presented the latest results from ongoing research at ESCMID Global 2025. ESCMID Global 2025 - the Congress of…
Mat Upton, CSO, presented new data at the 9th AMR conference in Basel on 25th February. It was suggested that…
Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in…
Amprologix files the first of a new series of patents protecting novel molecular structures for the treatment of bacterial infections.…
Innovate UK has awarded Amprologix £1M of Biomedical Catalyst funding to continue the Tobraderm project 1st March 2024 Amprologix is…
Mat Upton, CSO, presented the latest results from ongoing research at ESCMID Global 2025. ESCMID Global 2025 - the Congress of the European Society of Clinical Microbiology and Infectious Diseases - ran from April 11-15 in Vienna, and was attended by an audience of leading experts in infectious diseases and clinical microbiology. Amprologix presented results from […]
Mat Upton, CSO, presented new data at the 9th AMR conference in Basel on 25th February. It was suggested that probably half the global antimicrobial R&D activity was represented by attendees in the room. In a recent robust skin infection model with MRSA strain USA300, data demonstrate that a single daily dose of lead antibiotic […]
Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in London on 18th November 2024. We look forward to meeting industry partners and investors who share our passion for developing new treatments to combat the rising global threat from antimicrobial resistance, including superbugs like MRSA and VRE. For […]
